Difference between revisions of "Testosterone"

From Libre Pathology
Jump to navigation Jump to search
(create)
 
Line 3: Line 3:
==General==
==General==
*Driver of [[prostate cancer]].
*Driver of [[prostate cancer]].
*Testosterone target <0.7 nmol/L.<ref>{{Cite journal  | last1 = Shayegan | first1 = B. | last2 = Pouliot | first2 = F. | last3 = So | first3 = A. | last4 = Fernandes | first4 = J. | last5 = Macri | first5 = J. | title = Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians. | journal = Can Urol Assoc J | volume = 11 | issue = 6 | pages = 204-209 | month = Jun | year = 2017 | doi = 10.5489/cuaj.4539 | PMID = 28652880 }}</ref>
*Testosterone (chemical castration) target: <0.7 nmol/L.<ref>{{Cite journal  | last1 = Shayegan | first1 = B. | last2 = Pouliot | first2 = F. | last3 = So | first3 = A. | last4 = Fernandes | first4 = J. | last5 = Macri | first5 = J. | title = Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians. | journal = Can Urol Assoc J | volume = 11 | issue = 6 | pages = 204-209 | month = Jun | year = 2017 | doi = 10.5489/cuaj.4539 | PMID = 28652880 }}</ref>


==References==
==References==

Revision as of 12:30, 14 April 2018

Testosterone is sex hormone.

General

References

  1. Shayegan, B.; Pouliot, F.; So, A.; Fernandes, J.; Macri, J. (Jun 2017). "Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians.". Can Urol Assoc J 11 (6): 204-209. doi:10.5489/cuaj.4539. PMID 28652880.